BioSpace News Archive

Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, presents new preliminaryclinical data from a Phase I/IIa study of Temferon in patients affected by glioblastoma multiforme at the 2020 Society for Neuro-Oncology Annual Meeting, taking place November 19-22 in Austin, TX.

iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, announced positive one-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery device, MINIjectTM.

A novel outpatient procedure offers lasting pain relief for patients suffering from moderate to severe arthritis in their hip and shoulder joints, according to a study presented at the annual meeting of the Radiological Society of North America.

Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders, announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president, and founder, will present at the Stifel Virtual Healthcare Conference taking place November 16-18, 2020.

Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market

Nordic Nanovector ASA announces that it will report its results for the third quarter 2020 on Thursday, 19 November 2020.

Best practice recommendations establish national standard and address issues important to care in Canada

Biological E. Limited, Dynavax Technologies Corporation, and Baylor College of Medicine announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.

Myricx Pharma, a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases in cancer, unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brandon Capital Partners.

Second phase of operation will prioritize research projects with potential to help patients within the next six months